Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 9/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15359680 | 0.79 | HSD17B10 (0.62) | IDO1HSD17B10LMNASMN1; SMN2MAPT | |
| SCHEMBL880238 | 0.77 | ALDH1A1 (0.51) | IDO1HSD17B10LMNASMN1; SMN2MAPT | |
| SCHEMBL6855803 | 0.74 | LMNA (0.54) | LMNASMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL30325218 | 0.73 | IDO1 (0.61) | IDO1LMNA | |
| SCHEMBL880290 | 0.71 | HSD17B10 (0.62) | NPC1IDO1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL880307 | 0.67 | IDO1 (0.70) | IDO1HSD17B10LMNASMN1; SMN2MAPT | |
| SCHEMBL880476 | 0.65 | LMNA (0.52) | IDO1HSD17B10LMNASMN1; SMN2MAPT | |
| SCHEMBL880274 | 0.65 | HSD17B10 (0.56) | IDO1HSD17B10LMNASMN1; SMN2MAPT | |
| SCHEMBL10280721 | 0.63 | LMNA (0.54) | IDO1HSD17B10LMNASMN1; SMN2MAPT | |
| SCHEMBL13522397 | 0.63 | MAPT (0.68) | NPC1IDO1HSD17B10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-08-27 | — | — | US | disclosed |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013096820-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | NPC1 1809/4885IDO1 4493/4885HSD17B10 4015/4885 |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | NPC1 1809/4885IDO1 4493/4885HSD17B10 4015/4885 |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | NPC1 1809/4885IDO1 4493/4885HSD17B10 4015/4885 |
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | NPC1 1809/4885IDO1 4493/4885HSD17B10 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.